Developing new MRI methods to image the heart and organs

Trial details

Who runs it

National Heart, Lung, and Blood Institute (NHLBI)

Trial code

NCT03581318

Record updated

5 October 2026

Original description

Background:Read full original descriptionShow less

Technical and Translational Development of Cardiovascular MRI (CMR)

Background:

Magnetic resonance imaging (MRI) is an important non-invasive tool to study and diagnose cardiovascular disease. MRI scanners use strong magnetic fields and radio waves to create pictures of body organs. Researchers want to find better MRI methods and new ways of imaging cardiovascular disease and better understand normal and abnormal cardiovascular and brain function. Researchers are also interested in seeing if gadolinium, the commonly used MRI contrast agent, stays in the body long after the MRI was performed.

Objectives:

To develop new methods for imaging the heart and other organs of the body.

To describe cardiovascular diseases using newer MRI methods

To look at the relationship between cardiovascular disease and cardiovascular risk factors and other organ systems

To look for gadolinium deposits in the brain from prior exams.

Eligibility:

Healthy people and people with known or suspected cardiovascular disease ages 7 and older may be eligible for this study.

Researchers may be particularly interested in those who:

* Have suspected or known cardiovascular disease * Were previously exposed to a gadolinium-based contrast agent, * Need to have a heart MRI scheduled * Need a test of the heart or other body part or will be undergoing a future cardiac catheterization

Design:

There are multiple arms to the study with optional components; therefore, there are multiple variations as to what an individual participant s experience may involve.

Participants will have an MRI scan lasting up to 2 hours. The scanner is a large hollow tube. During the scan, there may be loud knocking and buzzing sounds caused by the scanner. Participants will lie on a table that slides in and out of the tube. Their vital signs may be monitored.

Participants may have a test of heart electrical activity using wires connected to pads on the skin.

Participants may have blood drawn.

Participants may be injected with an MRI contrast agent through a plastic tube inserted in the arm.

Inclusion: Age >= 7 years; Subjects with known or suspected cardiovascular disease; Able to provide informed consent in writing or provide guardian consent; Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events; Age >= 7 years; Able to provide informed consent in writing or provide guardian consent; Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events; Known or suspected brain, hematology, oncology, endocrine, pulmonary, or other non-cardiac disease.

Exclusion: If receiving contrast, breast feeding women (unless subject is willing to discard breast milk for 24 hours) are excluded; Breast feeding (unless subject is willing to discard breast milk for 24 hours if receiving contrast); Breast feeding in those subjects receiving contrast (unless subject is willing to discard breast milk for 24 hours; Important past or chronic medical illness such as major cardiovascular conditions like myocardial infarction, congenital heart disease, and known cardiomyopathy; Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:; Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI; Cerebral aneurysm clip unless it is labeled safe for MRI; Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI; Any type of ear or cochlear implant unless it is labeled safe for MRI; Ocular foreign body (e.g. metal shavings); Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI; Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI; Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:; Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI; Cerebral aneurysm clip unless it is labeled safe for MRI; Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI; Any type of ear or cochlear implant unless it is labeled safe for MRI; Ocular foreign body (e.g. metal shavings); Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI; Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI; Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate screening form) including:; Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI; Cerebral aneurysm clip unless it is labeled safe for MRI; Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI; Any type of ear or cochlear implant unless it is labeled safe for MRI; Ocular foreign body (e.g. metal shavings); Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI; Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI; eGFR < 60 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or equivalent (using the CRIScalculated eGFR to define the threshold) and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents; Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will under serum or urine pregnancy testing within 7 days of the day prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing; Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing 7 days prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing; eGFR < 30 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or Community Practice Standard for Pediatric case or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents; Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing on the day of the examination. In addition, the subject will be asked if she may be pregnant prior to the; performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing; eGFR < 30 mL/min/1.73m\^2 using the 2021 CKD-EPI equation or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents; Healthy volunteer children will not have contrast; In a year's time, healthy volunteers are not restricted as to the number of non-contrast MRI examinations they undergo, but they may not undergo more than two examinations involving gadolinium-based contrast agents (GBCA) and those exposures will be at least 18 hours (12 half-lives) apart; Cardiorespiratory instability as determined by the enrolling clinician; Cardiorespiratory instability or as determined by the enrolling clinician.

INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:; Age >= 7 years; Able to follow instructions and lie still in the MRI scanner; Currently without known Cardiovascular disease; Able to provide informed consent in writing or provide guardian consent; Willingness to cooperate with all study procedures and available for scheduled study events.

ClinicalTrials.gov NCT03581318